Structural modifications of the tumor necrosis factor-α inhibitor Enbrel affect its therapeutic efficacy in a mouse model of rheumatoid arthritis
The Journal of Pharmacology and Experimental Therapeutics · 2026-03 · 393 (3) · 103804
DOI: 10.1016/j.jpet.2026.103804 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pharmacology and Experimental Therapeutics, 2026-03. Verfasst von Rachel Birnboim-Perach und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Biotechnology, The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sci…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Tumor Necrosis Factor-alpha, Etanercept. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Israel Science Foundation, Tel Aviv University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Therapeutic blockade of proinflammatory cytokines has revolutionized the treatment of rheumatoid arthritis (RA), leading to the approval of several therapeutic biologics for RA. A prominent target in RA is tumor necrosis factor-α (TNF-α), a proinflammatory cytokine. Etanercept (Enbrel), a fusion protein comprising the soluble portion of the p75-TNF receptor and the Fc fragment of human IgG1 (hinge, CH2, and CH3 domains) was the first TNF-α specific biologic to make a substantial impact for the treatment of RA. Enbrel (etanercept) differs structurally and functionally from other anti-TNF-α biologics (monoclonal antibodies), primarily because of its unique structure. This study aimed to explore whether structural modifications of Enbrel with specific focus on isotype variation and the incorporation of the CH1 domain to the Fc constant region, can potentiate its therapeutic efficacy. We developed 4 murine versions of Enbrel: mEnbrel2a and mEnbrel1, with and without the CH1 domain. These versions were assessed for their ability to bind and neutralize TNF-α in vitro, as well as their therapeutic effects in vivo using an experimental RA mouse model. We found that all mEnbrel variants bound TNF-α with comparable affinities. However, the mEnbrel2a derivatives, particularly with the CH1 domain, exhibited superior TNF-α neutralization in vitro. In vivo, mEnbrel2a with a CH1 domain provided the most significant reduction in disease severity. These findings underscore the critical role of isotype and domain selection in optimizing the therapeutic potential of Fc-fusion proteins and provide valuable insights applicable to other Fc-fusion proteins and a broader range of pathologies. SIGNIFICANCE STATEMENT: This study reveals that isotype and Fc domain engineering of tumor necrosis factor-α-targeting biologics enhances therapeutic efficacy against rheumatoid arthritis in a mouse model. Specifically, incorporation of the CH1 domain into an Enbrel-based Fc-fusion protein of the mouse IgG2a isotype significantly improved disease outcomes (delay of onset, arthritis severity, reduction in inflammatory white blood cells), highlighting the importance of Fc configuration for optimizing mEnbrel. These findings provide a foundation for the rational design of next-generation Fc-fusion therapeutics for autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Microbiology and Biotechnology, The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
- Department of Pathology, Wolfson Medical Center, Holon, Israel.
- Department of Molecular Microbiology and Biotechnology, The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel; Cancer Biology Research…
Förderung
- Israel Science Foundation
- Tel Aviv University
- National Natural Science Foundation of China
Zitieren
APA
Birnboim-Perach, R., Aharon, A., Amir, A., Grotto, O., Palgi-Shloosh, M., Diesendruck, Y., Beltran, N., Nahary, L., & Benhar, I. (2026). Structural modifications of the tumor necrosis factor-α inhibitor Enbrel affect its therapeutic efficacy in a mouse model of rheumatoid arthritis. The Journal of Pharmacology and Experimental Therapeutics, 393(3), 103804. https://doi.org/10.1016/j.jpet.2026.103804
Vancouver
Birnboim-Perach R, Aharon A, Amir A, Grotto O, Palgi-Shloosh M, Diesendruck Y, et al. Structural modifications of the tumor necrosis factor-α inhibitor Enbrel affect its therapeutic efficacy in a mouse model of rheumatoid arthritis. The Journal of Pharmacology and Experimental Therapeutics. 2026;393(3):103804. doi:10.1016/j.jpet.2026.103804
BibTeX
@article{BirnboimPerach2026,
author = {Birnboim-Perach, Rachel and Aharon, Adi and Amir, Adi and Grotto, Omer and Palgi-Shloosh, May and Diesendruck, Yael and Beltran, Nitzan and Nahary, Limor and Benhar, Itai},
title = {Structural modifications of the tumor necrosis factor-α inhibitor Enbrel affect its therapeutic efficacy in a mouse model of rheumatoid arthritis},
journal = {The Journal of Pharmacology and Experimental Therapeutics},
year = {2026},
volume = {393},
number = {3},
pages = {103804},
doi = {10.1016/j.jpet.2026.103804}
}
EUVIMED